Protagenic Therapeutics ( (PTIX) ) just unveiled an update.
On February 21, 2025, Protagenic Therapeutics Inc. held its 2024 Annual Meeting of Stockholders, where stockholders approved a proposal to reprice certain outstanding stock options under the company’s 2006 and 2016 Equity Incentive Plans. The Board of Directors subsequently repriced these options to an exercise price of $0.2655 per share, aligning with the closing price of the company’s common stock on that date, potentially impacting the company’s financial strategy and stakeholder interests.
More about Protagenic Therapeutics
Protagenic Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for neurological and stress-related disorders. The company is engaged in creating innovative treatment options to address unmet medical needs in mental health.
YTD Price Performance: -48.94%
Average Trading Volume: 420,616
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.92M
See more data about PTIX stock on TipRanks’ Stock Analysis page.